global-women-health-orthopedics-congress-2018-posters

Page 45

S e p t e m b e r 0 6 - 0 7 , 2 0 1 8 | B a n g k o k , T h a i l a n d

allied

academies

Joint Event on

Global Women Health 2018 & Orthopedics Congress 2018

Archives of General Internal Medicine

ISSN: 2591-7951

Volume 2

BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH

ORTHOPEDICS AND RHEUMATOLOGY

World Congress on

Annual Conference on

Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C3-009

MODERN ROLE OF REPEATED COURSES ANTENATAL CORTICOSTEROIDS

IN PTL

Sheashaa A

Cairo University, Egypt

ebirth of use of progesterone in prevention of preterm birth. Preterm birth is currently the most important problem in maternal-

child health throughout the world. It complicates one in eight US deliveries, and accounts for over 85% of all perinatal morbidity

andmortality. Although survival of preterm infants has increased steadily over the past four decades, efforts to prevent pretermbirth

have been largely unsuccessful. The US Food and Drug Administration (FDA) on February 3, 2011) approved the use of progesterone

supplementation (hydroxyl progesterone caproate) during pregnancy to reduce the risk of recurrent preterm birth in women with

a history of at least one prior spontaneous preterm delivery. This is the first time that the FDA has approved a medication for the

prevention of preterm birth specifically for use in pregnancy in almost 15 years. Progesterone supplementation reduces the risk

of preterm birth by about one-third in women with a singleton pregnancy who have had a previous spontaneous singleton preterm

birth and in women with a short cervix on ultrasound examination in the current pregnancy. For women with mid trimester cervical

shortening (defined as ≤20 mm before 24 weeks) and no prior spontaneous singleton preterm birth, vaginal progesterone treatment

200 mg daily through the 36 weeks of gestation is suggested as a reasonable option. Routine progesterone supplementation does

not appear to be useful for preventing preterm birth. For, women with twin pregnancies and a previous spontaneous preterm birth.

In women with preterm premature rupture of membranes or after an episode of arrested preterm labor or with cerclage, the effect

on efficacy is unclear.